According to the press release, the pharmaceutical companies claimed that there was an “urgent public health need” for children under the age of five to get vaccinated against SARS-CoV-2.
Citing that in the week ending January 22, children under four accounted for 3.2 percent of the total hospitalizations “due to COVID-19,” Pfizer CEO Albert Bourla said that “our mutual goal with the FDA is to prepare for future variant surges and provide parents with an option to help protect their children from this virus.”
It is not clear how the vaccine that was developed against the original strain of the Wuhan virus (that is already proven to stop neither infection nor transmission) would help “prepare for future variant surges.” Worse yet, the vaccines are connected to the emergence of the later coronavirus variants, non-establishment scientists say.
Bourla said that children under five would most likely require three doses “to achieve high levels of protection against current and potential future variants.” Back in December 2021, the company said that the two-dose regimen did not produce the “required” immune response in young children and, per the Associated Press report, the third shot should come at least two months after the youngsters receive their second one.
The clinical studies on the third dose are still ongoing but, while the results are pending, the FDA will be asked to approve two initial doses.
Dr. Ugur Sahin, CEO and co-founder of BioNTech, said, “Our vaccine has already demonstrated a favorable safety, tolerability and efficacy profile in multiple clinical trials and real-world studies for all age groups starting from 5 years old.”
The press release also notes that the Pfizer-BioNTech clinical trials initially enrolled 4,500 children ages six months to under 12 years of age in the United States, Finland, Poland, and Spain, from more than 90 clinical trial sites.
The single dose given to children as young as six months was three micrograms, or a tenth of the adult dose.
The companies further stressed that “emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product.” In other words, the shots will not be fully licensed, yet the FDA would consider their use appropriate because of the “public health emergency” to which “no adequate, approved, and available alternatives” exist. Tragically, U.S. public health agencies do not consider COVID early treatments with outstanding safety and efficacy profiles such as ivermectin and hydroxychloroquine to be “adequate alternatives,” and even warn against their use.
Pfizer and BioNTech included “Important Safety Information” on their shots, starting with the warning against taking the vaccines if one has had a “severe allergic reaction” to the first dose, or has a known allergy to the shot’s ingredients.
The companies also note that people should “tell the vaccination provider” if they:
• have any allergies;
• have had myocarditis;
• have a fever;
• have a bleeding disorder or are on a blood thinner;
• are immunocompromised or are on a medicine that affects the immune system; or
• are pregnant, plan to become pregnant, or are breastfeeding.
They also warn that “the vaccine may not protect everyone.”
The release also warns of the potential “remote chance” of developing adverse reactions, including, but not limited to, severe rash, itching, hives, or swelling of the face, as well as possible myocarditis and pericarditis.
The companies even provide that “Serious and unexpected side effects may occur. The possible side effects of the vaccine are still being studied in clinical trials.” Indeed, all of the currently available COVID shots for adults have yet to complete clinical trials, with the earliest completion date set for May 2023.
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) is expected to meet February 15 to discuss the data Pfizer has presented on the two-dose series.
Is There an “Emergency?”
As of January 27, children of the age of 0 to four accounted for 0.1 percent of all deaths associated with COVID. The CDC attributed 287 deaths in children in that group to COVID, as of January 29.
Studies show COVID poses no danger to children. Johns Hopkins study showed a COVID mortality rate of zero among 48,000 healthy children. A major study in Germany found the case fatality rate among children is three out of a million with zero deaths reported in children under five.
While CDC Director Rochelle Walensky acknowledged at the end of December 2021 that that a substantial percentage of COVID-positive children were admitted for other reasons and tested positive for COVID while in the hospital, it did not prevent her from claiming just a week later that children were being hospitalized “at their highest rate” compared to any prior point in the pandemic.
The world’s top non-establishment scientists called on parents and decision-makers to exclude children from COVID vaccinations, arguing the risks do not outweigh the benefits.
While the health authorities and the Biden administration are promoting vaccinations among the youngest of Americans, the Vaccine Adverse Effects Reporting System (VAERS) shows the shots are far from safe. The data from December 14, 2020, to January 21, 2022 for 5- to 11-year-olds show, per Children’s Health Defense,
• 7,052 adverse events, including 152 rated as serious and 3 reported deaths.
The most recent death involves a seven-year-old girl (VAERS I.D. 1975356) from Minnesota who died 11 days after receiving her first dose of Pfizer’s COVID vaccine when she was found unresponsive by her mother. An autopsy is pending.
• 14 reports of myocarditis and pericarditis (heart inflammation).
• 24 reports of blood clotting disorders.
One should keep in mind that the U.S. government itself has admitted that VAERS reflects only one percent of actual vaccine adverse events.
